Author: Ravi Shankar

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Talisker Resources Ltd. (“Talisker”) (TSX: TSK; OTCQX: TSKFF), a junior resource company involved in the exploration and development of gold projects in British Columbia, has qualified to trade on the OTCQX® Best Market. Talisker upgraded to OTCQX from the OTCQB® Venture Market.

Talisker begins trading today on OTCQX under the symbol “TSKFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

As one of the largest holders of mineral claims in British Columbia, Talisker has successfully made the transition from explorer, developer to gold producer with its first producing gold mine, the Mustang Mine transitioned into production in H2 2025. Talisker plans to develop numerous mining centres over the 40km strike length of the company’s 100% owned Bralorne Gold Project with a view to achieve its corporate vision of 200,000 ounces of annual gold production. With a global resource of 3.45M oz of with an average grade in excess of 8 g/t Talisker presents a real gold mining growth opportunity. 

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Terry Harbort, CEO of Talisker stated, “We are pleased to have re-qualified for trading on the OTCQX Market which we anticipate will provide Talisker with wider visibility to the US investment community.”

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an advanced stage project with significant exploration potential from an historical high-grade producing gold mine and the Spences Bridge Project where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, and several other early-stage Greenfields projects.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:

OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4

Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001

ORKA-001 maintained a favorable safety and tolerability profile through Week 28

52-week EVERLAST-A data for all patients expected in December 2026

16-week EVERLAST-B data expected in 4Q 2026

MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.

“These Week 28 results, with responses continuing to deepen months after the last dose, point to the incredible potential of ORKA-001,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “With over 70% of patients achieving completely clear skin after just two induction doses and a safety profile consistent with the IL-23 class, ORKA-001 has the potential to redefine the standard of care for psoriasis. We look forward to sharing the full 52-week data later this year.”

“The depth of clearance seen at Week 28, achieved without any dosing beyond Week 4, is remarkable,” said Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and lead investigator for EVERLAST-A. “To see PASI 100 rates continue to climb over time speaks to the potential of this molecule. The emerging profile of ORKA-001 could offer patients substantial disease control along with very infrequent dosing.”

EVERLAST-A is a randomized, double-blind, placebo-controlled Phase 2a trial evaluating the safety, efficacy, and pharmacokinetics of ORKA-001 in patients with moderate-to-severe plaque psoriasis. The study is being conducted across 26 sites in the United States and Canada and enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Week 0 and 4 or matching placebo. Patients who initially received placebo received 600 mg of ORKA-001 at Week 16 and 20. The study continues through Week 52 to assess durability of response, maintenance dosing, and long-term safety.

Efficacy

As previously reported, 63.5% of patients (40 of 63) treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16. Clinical responses continued to deepen through Week 28, six months after the last dose of ORKA-001. PASI 100 response rates increased to 71.4% (45 of 63) and PASI 90 response rates increased to 87.3% (55 of 63) at Week 28. IGA 0/1 response rates were maintained at 84.1% (53 of 63).

Patients who initially received placebo and crossed over blinded to ORKA-001 at Week 16 demonstrated a similar pattern of clinical response to those initially receiving ORKA-001. In this dosing arm, 40.0% (8 of 20) achieved PASI 100 at Week 28 (12 weeks after dosing) compared to 42.9% (27 of 63) of patients in the active arm at the equivalent timepoint.

Safety

ORKA-001 continues to be well tolerated, with a safety profile consistent with the IL-23p19 class. Between Weeks 16-28, the only treatment-emergent adverse event in ≥5% of patients receiving ORKA-001 was upper respiratory tract infection, occurring in 8% (7 of 83) of patients. Two patients experienced serious adverse events, neither deemed drug related: one tibial fracture and one case of prostate adenocarcinoma in a patient with elevated prostate-specific antigen (PSA) at baseline. There continue to be no injection site reactions. No impact of anti-drug antibodies on safety, efficacy, or PK has been observed.

Upcoming Milestones for ORKA-001 

Oruka plans to share longer-term data from EVERLAST-A, including efficacy at Week 52 for all patients, in December 2026. The Company also continues to advance the EVERLAST-B Phase 2b trial of ORKA-001, with data expected during the fourth quarter of 2026. 

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. 

Forward Looking Statements

Certain statements in this press release, other than statements of historical fact, are “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding: the potential therapeutic benefits, efficacy, safety, tolerability, durability of response and dosing profile of ORKA-001; the potential for ORKA-001 to provide durable disease control with infrequent dosing; the planned conduct, progress, timing and results of the EVERLAST-A and EVERLAST-B trials; and the anticipated timing of clinical data readouts. These forward-looking statements are based on Oruka’s current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law. 

Investor Contact:

Alan Lada
(650)-606-7911
alan.lada@orukatx.com

NORWOOD, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with a Special Meeting of Stockholders (the “Special Meeting”) to seek stockholder approval of a proposed reverse stock split of the Company’s common stock (the “Reverse Stock Split”).

The proposed Reverse Stock Split is intended to provide MariMed with greater flexibility to satisfy the minimum share price and other requirements associated with a potential listing of its common stock on a U.S. national securities exchange. If the proposal is approved by the Company’s stockholders, the Reverse Stock Split will be effected in the sole discretion of the Board of Directors (the “Board”).

“Our Board believes that positioning MariMed to pursue a listing on a major U.S. exchange is an important step in the Company’s evolution,” said Jon Levine, Chief Executive Officer of MariMed. “A national exchange listing has the potential to broaden our investor base by increasing the Company’s visibility among institutional investors, research analysts and broker-dealers and improve access to the capital markets. As the regulatory environment for the cannabis industry as well as the capital markets continue to evolve, we believe taking these steps now gives us greater strategic flexibility.”

There can be no assurance that the Board will determine to effect the Reverse Stock Split, that MariMed will be eligible for listing on a U.S. national securities exchange, that the Reverse Stock Split will enable the Company to satisfy all applicable listing requirements, or that the Reverse Stock Split will result in a sustained increase in the trading price or liquidity of the Company’s common stock.

Reverse Stock Split Details

If approved by stockholders:

• The Reverse Stock Split proposal would authorize the Board to determine whether and when to implement the Reverse Stock Split at a ratio of between one for fifty and one for one-hundred, in its discretion. The Board would determine the final ratio based on market conditions and other relevant considerations, including the requirements associated with a potential listing of the Company’s common stock on a U.S. national securities exchange.
• The Board would retain the discretion not to implement the Reverse Stock Split if it determines that doing so would not be in the best interests of the Company and its stockholders.

• No fractional shares would be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split will instead receive a cash payment in lieu of such fractional share.

If the Reverse Stock Split is implemented:

• The number of shares of MariMed common stock outstanding would be reduced by the applicable split ratio. The Reverse Stock Split would not, by itself, change a stockholder’s proportional ownership or voting power in the Company, except for any adjustments resulting from the treatment of fractional shares.

Special Meeting of Stockholders

The Special Meeting is scheduled to be held virtually on October 28, 2026 at 9:30 am eastern time, or a later date if adjourned. Stockholders of record as of the close of business on September 4, 2026 will be entitled to vote on the Reverse Stock Split proposal at the Special Meeting.

The definitive proxy statement has been filed with the SEC and is available through the SEC’s website and on MariMed’s Investor Relations website. Stockholders are encouraged to read the definitive proxy statement in its entirety because it contains important information regarding the Reverse Stock Split proposal, including the reasons for the proposal and associated risks.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in connection with the proposal to be submitted to the Company’s stockholders at the Special Meeting seeking approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split Proposal”). This communication does not contain all the information that should be considered concerning the Reverse Stock Split Proposal and is not intended to form the basis of any investment decision or any other decision in respect of the Reverse Stock Split Proposal. In connection with the Special Meeting, the Company filed a definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on September 22, 2026. The Company’s stockholders are urged to read the definitive proxy statement and all other relevant materials filed with the SEC as such documents contain important information about the Company, the Special Meeting and the Reverse Stock Split Proposal. The definitive proxy statement and other relevant materials are being made available to the Company’s stockholders as of the record date for the Special Meeting and may be obtained free of charge at the SEC’s website, www.sec.gov, or via the Company’s website, www.marimedinc.com.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the Reverse Stock Split Proposal. Information about the Company’s directors and executive officers, including a description of their direct or indirect interests in the Reverse Stock Split Proposal, is set forth in the definitive proxy statement for the Special Meeting filed with the SEC on September 22, 2026. The definitive proxy statement may be obtained free of charge from the sources indicated above.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Important Caution Regarding Forward-Looking Statements
The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties. All statements other than statements of historical facts contained in this release, including without limitation statements regarding the proposed listing of the Company’s common stock on a national exchange and the affect and impact of the Reverse Split are forward-looking statements. Without limiting the foregoing, the words “anticipates,” “believes,” “estimates,” “expects,” “expectations,” “intends,” “may,” “plans,” and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on the Company’s current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, its ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect the Company’s business and results of operations. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in the Company’s reports filed with the U.S. Securities and Exchange Commission. In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

For More Information Contact:

Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — On September 22, 2026, the Board of Directors of AGF Management Limited declared a dividend of 13.5 cents per share on both the Class B Non-Voting shares and the Class A Voting common shares of the company. This dividend will be payable on October 15, 2026 to shareholders of record on October 1, 2026.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.

AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.

Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $74 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

AGF Management Limited shareholders, analysts and media, please contact:

Nick Smerek
VP, Financial Planning & Analysis
416-865-4337, InvestorRelations@agf.com

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) —

• Reported quarterly adjusted diluted earnings per share of $0.49
• Free cash flows of $38.9 million in the quarter, up 27% from prior year
• Total assets under management and fee-earning assets of $74.2 billion, up 31% from prior year
• Declared quarterly dividend per share of 13.5 cents

AGF Management Limited (AGF or the Company) (TSX: AGF.B) today announced financial results for the third quarter ended August 31, 2026.

AGF reported total assets under management and fee-earning assets¹ of $74.2 billion compared to $74.7 billion in the prior period and $56.8 billion in the comparative prior year period. AGF generated strong free cash flows of $38.9 million in the quarter, up 27% from the prior year.

“We are pleased with the progress we have made through the first three quarters of the year. Our teams continue to execute against our strategic priorities, strengthen our business and deepen relationships with clients and partners,” said Judy Goldring, Chief Executive Officer, AGF Management Limited.

AGF Investments’ mutual fund gross sales were $1,366 million for the quarter compared to $1,363 million in the prior period and $1,260 million in the comparative prior year period. Canadian retail net flows² were $271.0 million for the quarter, compared to $161.0 million in the prior period and $309.0 million in the comparative prior year period.

“As we look ahead, we remain committed to our strategy and focused on the long term. We are building on our strong foundation, continuing to expand our capabilities and pursuing opportunities to drive growth. With a strong team, differentiated investment capabilities and a clear sense of where we are going, we are well positioned to continue creating value for our clients and shareholders,” added Goldring.

_{¹ AUM represents assets under management and model delivery assets of AGF subsidiaries and affiliates. Fee-earning assets represents assets managed by affiliates in which AGF has carried interest ownership and earns fees but does not have ownership interest in the managers.
² Canadian retail net flows includes Canadian retail mutual fund net sales and Canadian ETF and SMA net sales.}

Key Business Highlights:

AGF Investments

AGF Investments launched ETF series units for the AGF Enhanced U.S. Income Plus Fund (AENP), expanding the firm’s ETF lineup and providing investors with greater choice.

AGF Investments also continued to see strong demand across its ETF and separately managed account (SMA) offerings, reflecting growing interest in flexible investment solutions. During the quarter, the AGF U.S. Large Cap Growth Strategy was added to a leading U.S. advisory platform, further expanding SMA access and broadening the firm’s reach in the U.S. market.

AGF Capital Partners

In July, following an extensive global search, Kensington Capital Partners Limited, an affiliate manager of AGF Capital Partners, appointed industry veterans Saar Pikar and Bogdan Cenanovic to its senior leadership team, strengthening its depth and expertise to support the firm’s next phase of growth.

Financial Highlights:

• Adjusted EBITDA³ for the three months ended August 31, 2026 was $48.8 million, compared to $64.1 million for the three months ended May 31, 2026 and $46.2 million for the comparative prior year period.
• Net management, advisory and administration fees³ for the three months ended August 31, 2026 was $101.0 million, compared to $96.7 million for the three months ended May 31, 2026 and $88.8 million for the comparative prior year period.
• Adjusted selling, general and administrative costs³ for the three months ended August 31, 2026 was $63.7 million, compared to $62.6 million for the three months ended May 31, 2026 and $61.3 million for the comparative prior year period. Adjusted SG&A increased compared to the prior period and comparative prior year period, primarily driven by higher non-compensation expenses.
• Adjusted EBITDA³ from AGF Capital Partners for the three months ended August 31, 2026, was $8.5 million, compared to $21.5 million for the three months ended May 31, 2026 and $11.4 million for the comparative prior year period. The decrease over the prior period is primarily due to lower revenue from long-term investments and a $14.7 million gain recognized on the NHC transaction in the prior period.
• Adjusted EBITDA³ excluding AGF Capital Partners of $40.3 million for the three months ended August 31, 2026, compared to $42.6 million for the three months ended May 31, 2026 and $34.8 million for the comparative prior year period.
• Adjusted net income attributable to equity owners³ for the three months ended August 31, 2026 was $32.0 million ($0.49 adjusted diluted EPS), compared to $46.9 million ($0.72 adjusted diluted EPS) for the three months ended May 31, 2026 and $31.2 million ($0.46 adjusted diluted EPS) for the comparative prior year period.
• Free cash flow³ of $38.9 million for the three months ended August 31, 2026, compared to $36.4 million for the three months ended May 31, 2026 and $30.6 million for the comparative prior year period.

		Three months ended												Nine months ended
			August 31,				May 31,				August 31,				August 31,				August 31,
	(in millions of Canadian dollars, except per share data)		2026				2026				2025				2026				2025
	Revenues
	Management, advisory and administration fees	$	141.7			$	135.8			$	126.7			$	408.4			$	369.0
	Trailing commissions and investment advisory fees		(40.7	)			(39.1	)			(37.9	)			(118.3	)			(111.2	)
	Net management, advisory and administration fees3	$	101.0			$	96.7			$	88.8			$	290.1			$	257.8
	Deferred sales charges		0.6				0.8				0.9				2.3				3.1
	Adjusted revenue from AGF Capital Partners3		10.9				26.6				15.5				38.3				53.7
	Other revenue3		–				2.6				2.3				3.8				3.4
	Total adjusted net revenue3		112.5				126.7				107.5				334.5				318.0
	Selling, general and administrative		64.8				64.0				65.9				196.3				196.6
	Adjusted selling, general and administrative3		63.7				62.6				61.3				191.4				184.4
	EBITDA3		47.4				63.0				42.1				138.7				122.5
	EBITDA margin3		42.1%				49.7%				39.2%				41.4%				38.5%
	Adjusted EBITDA3		48.8				64.1				46.2				143.1				133.6
	Adjusted EBITDA margin3		43.4%				50.6%				43.0%				42.8%				42.0%
	Net income – equity owners of the Company		31.2				46.3				28.4				95.6				83.6
	Adjusted net income – equity owners of the Company3		32.0				46.9				31.2				98.6				89.3
	Diluted earnings per share		0.48				0.71				0.42				1.46				1.24
	Adjusted diluted earnings per share3		0.49				0.72				0.46				1.50				1.33
	Free cash flow3		38.9				36.4				30.6				111.2				86.2
	Dividends paid per share		0.135				0.135				0.125				0.395				0.365

_{³ Net management, advisory and administration fees, adjusted revenue from AGF Capital Partners, total adjusted net revenue, adjusted selling, general and administrative, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted diluted earnings per share and free cash flow are not standardized measures prescribed by IFRS. The Company utilizes non-IFRS measures to assess our overall performance and facilitate a comparison of quarterly and full-year results from period to period. They allow us to assess our investment management business without the impact of non-operational items. These non-IFRS measures may not be comparable with similar measures presented by other companies. These non-IFRS measures and reconciliations to IFRS, where necessary, are included in the Management’s Discussion and Analysis available at www.agf.com.}

		Three months ended
			August 31,				May 31,			February 28,			November 30,			August 31,
	(in millions of Canadian dollars)		2026				2026			2026			2025			2025
	Mutual fund AUM4	$	37,529			$	37,985		$	35,817		$	34,984		$	32,958
	ETFs and SMA AUM5		5,481				4,823			4,492			4,136			3,487
	Segregated accounts and sub-advisory AUM		5,874				6,634			5,923			7,190			6,685
	Total AGF Investments AUM		48,884				49,442			46,232			46,310			43,130
	AGF Private Wealth AUM		9,685				9,948			9,764			9,488			9,016
	AGF Capital Partners AUM6		13,533				13,178			2,345			2,454			2,510
	Total AUM	$	72,102			$	72,568		$	58,341		$	58,252		$	54,656
	AGF Capital Partners fee-earning assets7		2,133				2,129			2,120			2,136			2,121
	Total AUM and fee-earning assets7	$	74,235			$	74,697		$	60,461		$	60,388		$	56,777
	Mutual fund net sales (redemptions)		(30	)			6			190			276			247
	Canadian retail net flows2		271				161			431			488			309
	Canadian retail mutual fund net sales8		92				6			237			282			262
	Canadian ETF and SMA net sales5		179				155			194			206			47
	Average daily mutual fund AUM		38,045				35,869			35,154			34,424			32,122

_{⁴ Mutual fund AUM includes retail AUM, pooled funds AUM and institutional client AUM invested in customized series offered within mutual funds.
⁵ ETF and SMA AUM includes model delivery assets – third-party managed account assets for which AGF provides model portfolios and earns a model delivery fee, without custody or discretionary management of the underlying accounts.
⁶ AGF Capital Partners AUM represents the total assets under management of the Affiliate Managers that comprise AGF Capital Partners. This includes the full AUM of Affiliate Managers for which AGF consolidates or uses the equity method of accounting.
⁷ Fee-earning assets represents assets managed by affiliates in which AGF has carried interest ownership and earns fees but does not have ownership interest in the managers.
⁸ Net sales in retail mutual funds is calculated as reported mutual fund net sales (redemptions) less non-recurring institutional net sales (redemptions) in excess of $5.0 million invested in our mutual funds.}

For further information and detailed financial statements for the third quarter ended August 31, 2026, including Management’s Discussion and Analysis, which contains discussions of non-IFRS measures, please refer to AGF’s website at www.agf.com under ‘About AGF’ and ‘Investor Relations’ and at www.sedarplus.ca.

Conference Call

AGF will host a conference call to review its earnings results today at 11 a.m. ET.

The live audio webcast with supporting materials will be available in the Investor Relations section of AGF’s website at www.agf.com or at https://edge.media-server.com/mmc/p/iksbp2qy. Alternatively, the call can be accessed over the phone by registering here or in the Investor Relations section of AGF’s website at www.agf.com, to receive the dial-in numbers and unique PIN.

A complete archive of this discussion along with supporting materials will be available at the same webcast address within 24 hours of the end of the conference call.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.
 
AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.
 
Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $74 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

About AGF Investments

AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs. AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm and/or product is registered or authorized to provide such services.

About AGF Capital Partners

AGF Capital Partners is AGF’s multi-boutique alternatives business with Affiliate Managers across both private assets and alternative strategies. Clients benefit from the specialized investment expertise of Affiliate Managers combined with the organizational support and breadth of resources of AGF Management Limited (AGF). With over 19 years average experience, AGF Capital Partners Affiliate Managers including, Kensington Capital Partners Limited, New Holland Capital, LLC and AGF SAF Private Credit, manage approximately C$15.7 billion* in alternative AUM and fee earning assets on behalf of institutional and retail clients.

 *U.S. AUM converted FX rate as at August 31, 2026 (1.39)

The term ‘Affiliate Manager’ refers to any partner regardless of relationship structures or revenue sharing agreements. The form of AGF’s structured partnership interests in Affiliate Managers differs from Affiliate Manager to Affiliate Manager. The structure of the relationship with a particular Affiliate Manager, or the revenue that AGF agrees to share in, may change. Affiliate Managers only provide investment advisory services or offer products in the jurisdiction where such firm, individuals and/or product is registered or authorized to provide such services.

Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated.

AGF Management Limited shareholders, analysts and media, please contact:

Nick Smerek
VP, Financial Planning & Analysis
416-865-4337, InvestorRelations@agf.com

Caution Regarding Forward-Looking Statements

This press release includes forward-looking statements about the Company, including its business operations, strategy and expected financial performance and condition. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as ‘expects,’ ‘estimates,’ ‘anticipates,’ ‘intends,’ ‘plans,’ ‘believes’ or negative versions thereof and similar expressions, or future or conditional verbs such as ‘may,’ ‘will,’ ‘should,’ ‘would’ and ‘could.’ In addition, any statement that may be made concerning future financial performance (including income, revenues, earnings or growth rates), ongoing business strategies or prospects, fund performance, and possible future action on our part, is also a forward-looking statement. Forward-looking statements are based on certain factors and assumptions, including expected growth, results of operations, business prospects, business performance and opportunities. While we consider these factors and assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about our operations, economic factors and the financial services industry generally. They are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied by forward-looking statements made by us due to, but not limited to, important risk factors such as level of assets under our management, volume of sales and redemptions of our investment products, performance of our investment funds and of our investment managers and advisors, client-driven asset allocation decisions, pipeline, competitive fee levels for investment management products and administration, and competitive dealer compensation levels and cost efficiency in our investment management operations, as well as general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, taxation, changes in government regulations, unexpected judicial or regulatory proceedings, technological changes, cybersecurity, the possible effects of war or terrorist activities, outbreaks of disease or illness that affect local, national or international economies, natural disasters and disruptions to public infrastructure, such as transportation, communications, power or water supply or other catastrophic events, and our ability to complete strategic transactions and integrate acquisitions, and attract and retain key personnel. We caution that the foregoing list is not exhaustive. The reader is cautioned to consider these and other factors carefully and not place undue reliance on forward-looking statements. Other than specifically required by applicable laws, we are under no obligation (and expressly disclaim any such obligation) to update or alter the forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete discussion of the risk factors that may impact actual results, please refer to the ‘Risk Factors and Management of Risk’ section of the 2025 Annual MD&A.

CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the third quarter ending on September 30, 2026, before the market opens on Thursday, October 29, 2026.

A conference call and webcast with analysts and investors is scheduled for October 29, 2026, at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results.

• Investors and participants can register in advance for the call by visiting: https://register-conf.media-server.com/register/BI10964a36c81a483c80c6a571ef0f9518
• After registering, instructions will be shared on how to join the call for those who wish to dial in.
• On October 29, the live webcast can be accessed via the following link: https://edge.media-server.com/mmc/p/mr3yjhvp
• The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf^™ and MÜV^™ dispensary banners, and produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Savvy^™, (the) Essence^™, Swift Lifts^™, HYPHEN^™, Encore^™, Easy Landings^™, BITS^™, Avexia^™, MÜV^™, CTPharma^™, and Verano^™. Verano’s active operations span 13 U.S. states, comprised of 14 production facilities with over 1.1 million square feet of cultivation capacity. Learn more at Verano.com.

Contacts:
Investors
Verano
Aaron Miles
Chief Investment Officer
Investors@verano.com

Media
Verano
Steve Mazeika
Vice President, Communications
steve.mazeika@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

##

CHICAGO and VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced it will release third quarter 2026 financial results after the market closes on Wednesday, November 4, 2026.

A conference call and audio webcast will also be held on Wednesday, November 4, 2026, at 5:00 p.m. Eastern Time/4:00 p.m. Central Time to discuss the results and answer any questions.

• Live conference call: (800) 715-9871 (US & Canada) Conference ID: 4055374
• Live webcast: https://edge.media-server.com/mmc/p/drpfjbnk
• Archived webcast: https://investors.gtigrows.com/news-events/events-presentations

Cautionary Note Regarding Forward-Looking Information

This press release may contain forward-looking statements within the meaning of applicable securities laws. Such statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those implied by such statements. Green Thumb Industries undertakes no obligation to update any forward-looking statements, except as required by applicable law.

About Green Thumb Industries
Green Thumb Industries Inc. (“Green Thumb”) is a leading national cannabis consumer packaged goods company and retailer headquartered in Chicago, Illinois. The company manufactures and distributes a portfolio of licensed, branded cannabis products, including RYTHM, Dogwalkers, incredibles, Beboe, &Shine, Doctor Solomon’s and Good Green. Green Thumb also owns and operates RISE Dispensaries, a rapidly growing national retail chain. Green Thumb serves millions of patients and customers each year with a mission to promote well-being through the power of cannabis while giving back to the communities it serves. Established in 2014, Green Thumb has manufacturing facilities and retail stores across 14 U.S. markets, employing approximately 5,000 people. More information is available at www.gtigrows.com.

Investor Contact:
Andy Grossman
EVP, Capital Markets & Investor Relations
InvestorRelations@gtigrows.com
888-406-1143

Media Contact:
GTI Communications
media@gtigrows.com

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to provide additional results from its diamond drilling program at the Company’s Goliath Gold Complex, which includes the Goliath, Goldlund and Miller Deposits. The drill program, of which approximately 31,971 metres of the expanded 35-000 metre program have been completed, is focused on infilling and testing the extension of mineralization within Zone 4 of the Goldlund Deposit. The results presented in this news release include 3,603 metres of diamond drilling in 10 drill holes (GL-26-031 to GL-26-040) (Figures 1, 2 and 3; Tables 1 and 2).

Selected drill intersections from diamond drill holes at the Goldlund Deposit in this news release are further detailed in Table 1 and include:

• 14.07 g/t gold over 7.0 metres (from 187.0 to 194.0 metres), including 95.70 g/t gold over 1.0 metres in drill hole GL-26-034; additionally, 9.76 g/t gold over 8.0 metres (from 170.0 to 178.0 metres), including 74.10 g/t gold over 1.0 metres, 2.84 g/t gold over 13.0 metres (from 205.0 to 218.0 metres), including 21.70 g/t gold over 1.2 metres, 53.00 g/t gold over 1.0 metres (from 74.0 to 75.0 metres), and 0.55 g/t gold over 29.7 metres (from 243.5 to 273.2 metres) including 7.61 g/t gold over 1.2 metres in the same hole;
• 2.23 g/t gold over 15.5 metres (from 123.5 to 139.0 metres), including 40.50 g/t gold over 0.5 metres and 3.97 g/t gold over 0.8 metres in drill hole GL-26-032; additionally, 1.49 g/t gold over 9.1 metres (from 433.9 to 443.0 metres), including 6.50 g/t gold over 0.7 metres and 9.25 g/t gold over 0.5 metres in the same hole;
• 1.25 g/t gold over 22.0 metres (from 166.0 to 188.0 metres), including 40.50 g/t gold over 0.5 metres in drill hole GL-26-033; additionally, 0.84 g/t gold over 42.8 metres (from 245.7 to 288.5 metres), including 7.04 g/t gold over 1.3 metres and 3.91 g/t gold over 1.0 metres in the same hole; and
• 1.51 g/t gold over 17.1 metres (from 218.9 to 236.0 metres), including 13.80 g/t gold over 0.6 metres and 5.98 g/t gold over 1.0 metres in drill hole GL-26-039A; additionally, 2.04 g/t gold over 6.2 metres (from 196.2 to 202.4 metres), including 15.50 g/t gold over 0.6 metres in the same hole.

Kevin Bullock, President, CEO & Director of NexGold, commented: “I am pleased with the additional assay results from our drill program at Goldlund. This program continues to demonstrate grade continuity at depth, but within reach of a potential open pit. Grade tenor and thicknesses continue to build confidence that mineralization continues at depth and is consistent with previous drill results. Our continued drilling progress at Goldlund further supports our objectives for this program – to infill and test the extension of mineralization in Zone 4 – which is expected to contribute to refinement of our geological model and may inform future Mineral Resource assessments. We expect to complete the balance of the 35,000-metre program by the end of 2026 and will continue to provide updates as results become available.”

Mineralization at the Goldlund Deposit is generally characterized by quartz stockwork veining within sub-vertical granodiorite sills. Zone 4 at the Goldlund Deposit includes broad intervals of mineralized intermediate-mafic volcanic rocks with multiple porphyry and granodiorite intrusions. The drill results summarized in this news release, together with previously announced drill results, provide additional support and information relevant to the interpretation of grade continuity within Zone 4. These results are expected to contribute to ongoing refinement of the geological model and may support future evaluation of Mineral Resource classification, subject to additional drilling, data verification, and completion of further technical studies.

Drill holes completed as part of this program have been distributed across the strike extent of Zone 4, with the holes highlighted in this news release located from the central to southeastern portion of the zone. The results provide additional information supporting the Company’s current geological interpretation of mineralization within Zone 4 and provide additional information regarding the continuity of mineralization between drill sections. Additional drilling is planned to further evaluate mineralization along strike and down dip and to inform Mineral Resource assessments.

Figure 1: Plan map showing the location of the Goldlund Zone 4 infill drill holes

Figure 2: A cross-section through the Goldlund Deposit showing the location of the drill holes (GL-26-030B to GL-26-032 and GL-26-038 to GL-26-040) reported in this news release

Figure 3: A cross-section through the Goldlund Deposit showing the location of the drill holes (GL-26-033 to GL-26-035 and GL-26-037) reported in this news release

Table 1: Highlighted drill intercepts from drill holes in this news release

Drill Hole ID	Target/Zone	From (m)	To (m)	Interval (m)	Au (g/t)
GL-26-031	Zone 50	66.8	69.6	2.8	2.05
And	Zone 4	300.0	301.0	1.0	42.30
And	Zone 4	309.0	326.0	17.0	0.30
including		325.0	326.0	1.0	2.42
And	Zone 4	355.1	372.9	17.8	0.36
GL-26-032	Zone 50	123.5	139.0	15.5	2.23
Including		123.5	124.0	0.5	40.50
and including		136.2	137.0	0.8	3.97
And	Zone 4	433.9	443.0	9.1	1.49
Including		439.8	440.5	0.7	6.50
and including		442.5	443.0	0.5	9.25
GL-26-033	Interzone	21.0	27.0	6.0	1.01
Including		21.0	22.0	1.0	3.85
And	Interzone	38.0	39.0	1.0	7.26
And	Zone 4	166.0	188.0	22.0	1.25
Including		174.5	175.0	0.5	40.50
And	Zone 4	245.7	288.5	42.8	0.84
Including		249.5	250.8	1.3	7.04
and including		273.0	274.0	1.0	3.91
And	Zone 4	293.8	300.0	6.2	1.19
Including		299.0	300.0	1.0	3.09
And	Zone 4	309.0	314.7	5.7	2.13
Including		310.0	311.0	1.0	10.70
GL-26-034	Interzone	74.0	75.0	1.0	53.00
And	Zone 4	170.0	178.0	8.0	9.76
Including		173.0	174.0	1.0	74.10
And	Zone 4	187.0	194.0	7.0	14.07
Including		187.0	188.0	1.0	95.70
And	Zone 4	205.0	218.0	13.0	2.84
Including		216.8	218.0	1.2	21.70
And	Zone 4	223.0	232.9	9.9	0.70
Including		223.0	224.0	1.0	4.18
And	Zone 4	243.5	273.2	29.7	0.55
Including		272.0	273.2	1.2	7.61
And	Zone 4	299.0	304.5	5.5	0.95
Including		303.5	304.5	1.0	4.01
GL-26-035	Interzone	85.5	91.5	6.0	1.02
Including		90.0	91.5	1.5	4.05
And	Zone 4	195.0	212.0	17.0	0.46
Including		207.0	208.0	1.0	2.92
And	Zone 4	219.4	225.0	5.6	0.57
And	Zone 4	239.0	253.8	14.8	0.43
GL-26-036	Zone 4	146.0	149.0	3.0	1.02
Including		146.0	146.7	0.7	2.99
GL-26-037	Zone 4	176.5	182.0	5.5	1.07
Including		181.0	182.0	1.0	3.17
And	Zone 4	195.0	209.0	14.0	0.62
Including		206.0	207.0	1.0	2.31
GL-26-038	Zone 4	178.0	186.0	8.0	0.65
Including		185.0	186.0	1.0	2.52
And	Zone 4	192.9	193.4	0.5	26.80
GL-26-039A	Zone 4	196.2	202.4	6.2	2.04
Including		201.8	202.4	0.6	15.50
And	Zone 4	218.9	236.0	17.1	1.51
Including		218.9	219.5	0.6	13.80
and including		225.5	226.5	1.0	5.98
GL-26-040	Zone 4	216.1	227.6	11.5	0.81
Including		222.6	223.6	1.0	3.58

<sup>Notes:
1. Reported intervals are drilled core lengths and do not indicate true widths. True widths typically vary from 50 to 75% of the interval length, except for hole GL-26-033, where true width is estimated from 25 to 50% of interval length due to the steeper inclination drilled.
2. For duplicate samples, the average grade was used to calculate the intersection grade. All grades are uncapped.</sup>

Table 2: Locations and orientations of drill holes in this news release

Drill Hole ID	Easting	Northing	Elevation (m)	Length (m)	Azimuth	Inclination
GL-25-031	546884	5527816	415	450	131	-46
GL-25-032	546884	5527816	415	501	128	-55
GL-25-033	546699	5527562	418	402	140	-70
GL-25-034	546768	5527647	418	405	129	-54
GL-26-035	546768	5527647	418	372	129	-45
GL-26-036	546691	5527494	410	192	128	-52
GL-26-037	546694	5527607	415	327	132	-45
GL-26-038	547033	5527739	423	300	120	-46
GL-26-039A	547072	5527762	426	327	121	-46
GL-26-040	547102	5527764	427	327	119	-45

^{Note: Drill hole locations reported as Universal Transverse Mercator NAD83 Zone 15N coordinates}

QA / QC

The Company has implemented a quality assurance and quality control (“QA/QC”) program to ensure sampling and analysis of all exploration work is conducted in accordance with the CIM Exploration Best Practices Guidelines. Drill core is sawed in half with one-half of the core sample dispatched to the Activation Laboratories Ltd. laboratory in Dryden, Ontario. The other half of the core is retained for future assay verification and/or metallurgical testing. Other QA/QC procedures include the insertion of blanks and Canadian Reference Standards for every tenth sample in the sample stream. A quarter core duplicate is assayed every 20^th sample. The laboratory, which is independent of the Company, has its own QA/QC protocols, running standards and blanks with duplicate samples in each batch stream. Additional checks are routinely run on anomalous values including gravimetric analysis and pulp metallic screen fire assays. Gold analysis is conducted by lead collection, fire assay with atomic absorption, and/or gravimetric finish on a 50-gram sample. Check assays are conducted at a secondary independent ISO certified laboratory (in this case AGAT Laboratories located in Mississauga, Ontario) following the completion of a program.

Qualified Person

Paul McNeill, P.Geo., VP Exploration of NexGold, is a “Qualified Person” as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. McNeill has reviewed the available data, composites and QA/QC information related to the drill program and approved the scientific and technical disclosure contained in this news release on behalf of NexGold.

About NexGold Mining Corp.

NexGold is a gold-focused company with assets in Canada and Alaska, including the Goldboro Gold Project in Nova Scotia, the Goliath Gold Complex (which includes the Goliath, Goldlund and Miller deposits) in Northwestern Ontario, and additional exploration projects across Canada. NexGold also holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project in southeast Alaska. NexGold is committed to ongoing, meaningful engagement with regional communities and Indigenous Nations to support sustainable development, safe operations, and shared economic and social benefits.

Further details about NexGold, including a Feasibility Study for the Goldboro Gold Project and a Prefeasibility Study for the Goliath Gold Complex, are available under the Company’s issuer profile on www.sedarplus.ca and on NexGold’s website at www.nexgold.com.

Contact:

Kevin Bullock President & CEO (416) 214-4654 kbullock@nexgold.com

Greg DiTomaso Investor Relations (647) 547-5357 gditomaso@nexgold.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable United States securities laws (collectively, “forward-looking information”). Forward-looking information relates to future events or future performance and reflects management’s expectations and assumptions as of the date of this news release.

Forward-looking information contained in this news release includes, but is not limited to statements regarding the Company’s plans and objectives for the Goldlund drill program; the expected completion of the 35,000-metre drill program by the end of 2026; planned drilling to evaluate mineralization along strike and down dip; the contribution of drilling results to refinement of the Company’s geological model; the potential use of drilling results in future Mineral Resource assessments and evaluation of Mineral Resource classification; and the timing and availability of additional drilling results.

Forward-looking information is often, but not always, identified by words and phrases such as “plans”, “expects”, “is expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “believes”, “targets”, “potential”, “may”, “could”, “should”, “would”, “will” and similar words and expressions.

Forward-looking information contained in this news release is based on certain assumptions that management considers reasonable as of the date of this news release, including that exploration activities will proceed on the anticipated schedules; that contractors, personnel, equipment and supplies necessary to complete the drill program will remain available on acceptable terms; that assay and other results will be received within anticipated timeframes; that the Company’s geological interpretations based on existing information are reasonable; and that the Company will have sufficient financial resources to complete its planned exploration activities.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others: risks that exploration activities, including drilling, may not accurately predict the continuity, grade or extent of mineralization; that future drilling results may not support the Company’s geological interpretations or changes to Mineral Resources estimates or classifications; delays in drilling, receipt of assay results or other exploration activities; the availability of financing, personnel, equipment and contractors; fluctuations in commodity prices, exchange rates and market conditions; environmental, Indigenous, community, permitting and regulatory risks; health and safety risks; and other risks described in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca.

Although the Company believes that the assumptions and expectations reflected in the forward-looking information are reasonable, there can be no assurance that such information will prove to be accurate, and actual results and future events may differ materially from those anticipated. Readers should therefore not place undue reliance on forward-looking information. The forward-looking information contained in this news release is provided as of the date hereof, and the Company undertakes no obligation to update or revise such forward-looking information except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4356fdeb-b77b-4642-bfb5-91022466b000
https://www.globenewswire.com/NewsRoom/AttachmentNg/4cb356cf-0163-4da1-bd32-a0f9bb696bb4
https://www.globenewswire.com/NewsRoom/AttachmentNg/2536866c-f3c7-476e-8a82-7ec7b7f764cb

ROUYN-NORANDA, Quebec, Sept. 23, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to present its operational report for the month of August 2026 for its Sleeping Giant gold mine, located north of Amos, Quebec. The results demonstrate a marked acceleration of the mine’s restart plan, driven by an increase in mill processing and continuous improvement in the head grades fed.

Highlights:

• Gold production increase: Production of 344 ounces of gold during the month, representing a 91% increase compared to the 180 ounces produced in July.

• Tonnage and grades progressing at the mill: Processing 6,209 tonnes of ore at a growing average grade of 1.94 g/t.

• Continuous increase in underground workforce: Hiring of 6 new miners, bringing the total workforce dedicated to the mine to 149 workers, allowing for accelerated development.

• Underground infrastructure advancement: Completion of 175 m of track drifts and drawpoints, as well as 88 m of sub-levels.

• Finalization of the mining camp in September: 123 rooms will be available to accommodate the personnel required to achieve objectives.

• Hiring at the mill: A second shift team has been recruited. It will be fully operational in October, enabling day and night mill operations on a 4-3 schedule. This team optimization will allow the processing of up to 12,800 tonnes of ore per month.

• Conclusion of an official strategic partnership: Abcourt will now be able to welcome trainees from the Centre de formation professionnelle de la Baie-James (CFPBJ).

Table 1: Comparison of Mill Performance Indicators and Gold Production

Operational Indicator	July 2026	August 2026	Evolution
Tonnes milled	4,736 t	6,209 t	+ 1,473 t (+ 31.1 %)
Average grade (g/t)	1.36 g/t	1.94 g/t	+ 0.58 g/t (+ 42.6 %)
Recovery rate	86.8 %	88.9 %	+ 2.1 %
Ounces produced	180 oz	344 oz	+ 164 oz (+ 91%)
Gold Pours	715 oz *	201 oz	See note Below

* Explanatory Note: The high gold pour recorded in July (715 oz) resulted from a cleanup of the inventory accumulated in the milling circuits during a technical transition phase. The August data accurately reflects the restart of a regular and stable production cycle, supported by the solid progression of tonnage and grade.

UNDERGROUND:

Workforce Optimization and Underground Production

Recruitment continued in August with the integration of 6 new workers, bringing the team dedicated to the mine to 149 employees. In parallel, the training partnership with Technica is bearing fruit: 2 trainers are currently supervising 10 apprentice-miners, with the objective of developing our own internal pool of qualified workforce.

This increase in underground personnel has allowed several key work areas to progress.

Table 2: Current Status and Planning of Mining Sectors

Sector Zone	Development Progress	Planned Production Period
295-DAC5	512 m / 790 m	Mining in progress; completion planned for January 2027
235-Zone 20	481.1 m / 516 m	September – December 2026
235-Zone 3	251.22 m / 405 m	To come (post-development)
355-Zone 3N	Beginning of development. + 63.5 m *	To Come
235-Zone 4_5	Ore drift is completed. Track drift started at the end of August 2026 (+ 47.15 m) **	Multi-Year

* Note: No total data available for 355-Z3N (concept currently being finalized).
** Note: Overall data for zone 4_5 pending block model (BM).

Mutually Beneficial Partnership for the Next Generation of Miners

An alliance with the Centre de formation professionnelle de la Baie-James (CFPBJ) allows Abcourt to counter the labor shortage by welcoming freshly trained interns. Students benefit from a concrete immersion at the Sleeping Giant mine, with room and board and transportation included. For the company, this structuring program secures a direct pool of qualified workers to support the acceleration of its underground operations.

Geology and Exploration

Definition and resource conversion drilling activities actively focused on levels 355 and 915 with two drills in action. During the month, 25 holes were completed for a total of 3,064 meters of core. A total of 2,427 core samples were shipped for analysis. The Company also received and integrated 3,876 assay results into its database, allowing continuous updates to its block models and 3D modeling to optimize future mining plans.

Infrastructure, IT and Environment

Regarding surface infrastructure, Abcourt began excavation and preventive maintenance work at the tailings pond as well as a reorganization of the interior yard. The IT department carried out major optimizations, including the relocation of the GuideTI server to the Sleeping Giant site, the installation of a secondary Starlink system to guarantee network redundancy, and the configuration of a new Web server dedicated to tracking production and miners’ bonuses.

Perspectives

Abcourt management is fully engaged in preparing its 2026/2027 budget. No major capital expenditure (CAPEX) is required in the short term, with absolute priority remaining focused on increasing production rates and achieving maximum operational critical mass at the Sleeping Giant mine. A regular and scheduled maintenance plan will be carried out in due course but will not significantly affect production.

Pascal Hamelin, President and Chief Executive Officer of Abcourt, states: “The 91% increase in our gold production in August confirms the acceleration of the ramp-up at Sleeping Giant. This momentum continues into September, with our teams having already successfully hoisted 5,706 tonnes of ore and milled 4,761 tonnes. Thanks to the continuous arrival of labor and the addition of a second shift at the mill, we are building the critical mass to operate day and night starting this fall. Our absolute priority remains the constant increase of our production rates to maximize all our volumes.”

Qualified Person: Pascal Hamelin, P. Eng., President and Chief Executive Officer of the Company, has reviewed and approved the technical information contained in this press release. Mr. Hamelin is a Qualified Person as defined by National Instrument 43-101.

About Abcourt Mines Inc.

Abcourt Mines Inc. is a Canadian gold development company with strategic properties located in northwestern Quebec, Canada. Abcourt owns the Sleeping Giant mine and mill and the Flordin property where it concentrates its activities.

For further information on Abcourt Mines Inc., please visit our website www.abcourt.ca and the documents filed under our profile on the SEDAR+ website www.sedarplus.ca.

Pascal Hamelin	Dany Cenac Robert
President and Chief Executive Officer	VP Communication and Corporate Development
T: (819) 768-2857	T: (514) 722-2276, ext. 456
Email: phamelin@abcourt.com	Email: ir@abcourt.com

FORWARD-LOOKING STATEMENTS

Certain information contained in this press release may constitute “forward-looking information” within the meaning of Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “aims”, “expects”, “projects”, “intends”, “anticipates”, “estimates”, “could”, “should”, “likely”, or variations of such words and phrases or statements specifying that certain acts, events or results “could”, “should” occur, “will occur” or “will be achieved” or other similar expressions. Forward-looking statements are based on Abcourt’s estimates and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, level of activity, performance or achievements of Abcourt to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Forward-looking statements are subject to business and economic factors and uncertainties, as well as other factors that could cause actual results to differ materially from those forward-looking statements, including relevant assumptions and risk factors set forth in Abcourt’s public documents, available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Although Abcourt believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements. Unless required by applicable securities laws, Abcourt disclaims any intention or obligation to update or revise any of these forward-looking statements or information, whether in light of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange

Highlights

• The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).
• Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
• Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of which US$2.4 million has been committed, to support scientific development and pharmaceutical-grade manufacturing capabilities relevant to the planned U.S. program.
• Psyence BioMed and PsyLabs have agreed to a value-matched share exchange with a transaction value of approximately US$9 million on each side.

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today announced that it has agreed to make a cash investment of up to US$5 million in Psyence Labs Ltd. (“PsyLabs”), together with a value-matched share exchange between the two companies. The transactions are intended to support the scientific, manufacturing and development capabilities required for Psyence BioMed’s planned U.S. ibogaine program.

TIRC, registered and headquartered in Texas, has been established to provide a dedicated corporate structure through which the Company can coordinate its planned U.S. regulatory, clinical and development activities involving pharmaceutical-grade ibogaine.

The Company is currently evaluating the feasibility and design of a potential ibogaine clinical trial in Texas. Any clinical program would be subject to protocol development, regulatory review and authorization, institutional approvals, funding, site selection and other customary requirements.

Texas has emerged as an important state for publicly supported ibogaine research. Psyence BioMed believes that establishing a dedicated presence in the state positions the Company to participate in this developing research environment while building the regulatory and clinical infrastructure required for a potential U.S. development program.

Strategic Investment and Share Exchange

To support its planned development activities, Psyence BioMed has agreed to invest up to US$5 million in PsyLabs. The investment is intended to fund scientific work and the continued development of pharmaceutical-grade ibogaine manufacturing capabilities relevant to Psyence BioMed’s U.S. program. Psyence BioMed has irrevocably committed to subscribe for US$2.4 million (936 PsyLabs ordinary shares at US$2,564 per share, based on a pre-money equity valuation of PsyLabs of US$54 million) under its pro rata pre-emption entitlement in PsyLabs’ current financing round. The balance of up to US$2.6 million is a backstop commitment to subscribe for shares in that financing round not taken up by other PsyLabs shareholders, in up to two tranches of up to US$1.3 million each, payable upon certain milestones being achieved and other customary conditions. If the milestone tranches have not been called and completed by December 31, 2026, Psyence BioMed’s obligation to fund them will lapse.

In addition to the abovementioned investment, the Company and PsyLabs have also agreed to a reciprocal share-for-share exchange, with each component valued at approximately US$9 million, subject to applicable corporate and regulatory approvals, required Nasdaq notifications and other customary closing conditions. The share exchange agreement may be terminated by any party if closing has not occurred by November 30, 2026. Under the agreed terms:

• Psyence BioMed will issue 1,497,500 common shares to PsyLabs, representing approximately US$8.99 million in transaction value based on a deemed issue price of US$6.00 per PBM share; and
• PsyLabs will issue 3,473 ordinary shares to Psyence BioMed, representing an equivalent transaction value of approximately US$8.99 million based on an implied equity valuation of PsyLabs of US$60 million derived from an independent third-party valuation.

Psyence BioMed is making the cash investment, and will hold the PsyLabs shares to be issued under the share exchange, through its wholly-owned subsidiary, Psyence Biomed II Corp. The share exchange increases each company’s ownership interest in the other. Immediately prior to the transactions, PsyLabs held approximately 30.22% of Psyence BioMed’s issued and outstanding common shares, and Psyence BioMed held approximately 29.17% of PsyLabs’ issued and outstanding shares. Immediately following completion of the share exchange and the committed portion of the cash investment, PsyLabs will hold approximately 49.89% of Psyence BioMed’s issued and outstanding common shares, and Psyence BioMed will hold approximately 41.13% of PsyLabs’ issued and outstanding shares. The cash investment and the share exchange are related-party transactions. Psyence BioMed believes the transactions will more closely align its clinical and regulatory development activities with PsyLabs’ pharmaceutical-grade manufacturing and supply capabilities.

“Access to pharmaceutical-grade ibogaine is fundamental to the U.S. program we are planning,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed and TIRC. “Our investment in PsyLabs, together with the share exchange, is intended to align Psyence BioMed more closely with the manufacturing and supply capabilities we believe a regulated clinical program will require, while TIRC provides the dedicated U.S. structure through which we intend to advance that program. Our objective is to advance this program responsibly, supported by rigorous clinical research and pharmaceutical-grade manufacturing.”

“TIRC is intended to bring greater coordination to the regulatory, clinical and operational components of our planned U.S. program,” said Dr. John Thorne, Project Lead of TIRC. “We are now evaluating the requirements for a potential clinical trial, including the development plan, regulatory pathway, manufacturing documentation and necessary clinical capabilities.”

“PsyLabs has invested significant time and expertise in developing a controlled supply and manufacturing platform for pharmaceutical grade ibogaine,” said Tony Budden, Chief Executive Officer of PsyLabs. “This investment is intended to allow us to further develop that capability in support of Psyence BioMed’s planned U.S. program and the quality requirements associated with regulated clinical research.”

TIRC will initially draw upon Psyence BioMed’s existing legal, administrative and financial resources, with corporate oversight that includes Chief Financial Officer Warwick Corden-Lloyd and the Company’s in-house legal function.

ABOUT PSYENCE BIOMED

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

ABOUT PSYLABS

PsyLabs is a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. www.psylabs.life

CONTACTS

Psyence Biomedical Ltd. · ir@psyencebiomed.com · media@psyencebiomed.com · info@psyencebiomed.com · +1 416-477-1708

Investor contact: Michael Kydd, Investor Relations Advisor — michael@psyencebiomed.com

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the proposed share exchange and the proposed US$5 million cash investment by Psyence BioMed into PsyLabs and their anticipated terms, pricing, timing, completion and effects; the application of the proceeds of that investment; the resulting shareholdings of Psyence BioMed and PsyLabs in one another; the formation, capitalization, funding and intended role of TIRC; the Company’s ability to secure pharmaceutical-grade drug substance and the regulatory documentation required to support a United States program; the evaluation, funding, design, timing and conduct of any clinical trial in Texas; the Company’s ability to obtain and maintain required registrations, permits, quotas and licenses; its ability to participate in federal or state ibogaine programs; and its expected role in future research, development and commercialization activities relating to ibogaine. Such statements may be identified by words including will, expects, intends, plans, anticipates, believes, estimates and similar expressions.

These statements rest on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company’s ability to maintain licenses, permits, supply arrangements and third-party relationships. Risks and uncertainties that could cause actual results to differ materially include: that the investments and share exchange or the corporate arrangements described are not completed on the terms or timetable expected, or at all; that required board, shareholder, regulatory or stock exchange approvals are not obtained; dilution to existing shareholders and the concentration of ownership resulting from the share exchange; that the share exchange and the cash investment are transactions between related parties, and that the terms agreed may differ from those that would be agreed between unrelated parties; that the US$6.00 per PBM share price at which PBM shares are issued under the exchange may not be indicative of the value at which those shares can be realized; that the valuations used to price the exchange and the cash investment are not indicative of realizable value; changes in law, regulation or enforcement priorities in the United States, Southern Africa or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risk; competition and market adoption risk; financing risk; and the Company’s ability to maintain compliance with Nasdaq continued listing standards. This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update such statements.

The Company makes no medical, treatment or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research. Rigorous scientific research and clinical trials are required. Any references to ibogaine stock, inventory or doses are the Company’s best estimates only. References to GMP-compliant mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards, and do not themselves constitute a representation of formal certification or approval by any regulatory authority unless expressly stated. References to a planned clinical trial describe an activity under evaluation only; no trial has been commenced, and no regulatory application in respect of it has been filed or accepted. This communication is not an offer to sell or a solicitation of an offer to buy any securities.